<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1538973079464292&amp;ev=PageView&amp;noscript=1">
Why Biobanks Matter

Patient samples are a cornerstone of Lyme disease research. They: 

  • 1
    Provide insights into disease mechanisms
  • 2
    Enable discovery of reliable biomarkers
  • 3
    Support the development of new diagnostics and therapies

A well-curated biorepository ensures researchers have access to consistent, high-quality samples from patients at different stages of disease. 

GLA-Funded Biobanks

Vector (1)
2018 -- Boston Children’s Hospital: The Pedi Lyme Net Pediatric Biobank
Vector (2)
2008 -- Johns Hopkins University: The SLICE Study
Addressing a Critical Gap

One of the greatest barriers to progress in Lyme and other tick-borne disease research is the limited availability of well-characterized patient samples, especially those paired with detailed clinical data. Without this foundation, advancing diagnostics and treatments is nearly impossible. 

 

GLA recognized this unmet need early and has led efforts to build the infrastructure to close this gap. 

5b16e186a0564f2f600c02ee9c1934052d20b0bf
Beyond Specimens: Catalysts for Collaboration

A Lyme disease biobank is more than a collection of samples. It’s a collaborative hub that: 

  • Connects researchers and institutions 
  • Fuels innovation in diagnostics and treatments
  • Translates today’s research questions into tomorrow’s solutions for patients
41b24776d0fc7551c6b376a2589dc0ae544d3a8a